Kidney cancer journal : official journal of the Kidney Cancer Association最新文献

英文中文

Commentary for the KCJ article "Molecular and Immune Landscape of Fumarate Hydratase-Mutated Renal Cell Carcinoma". 为 KCJ 文章 "富马酸氢化酶突变的肾细胞癌的分子和免疫景观 "撰写评论。

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2023-12-01 Epub Date: 2022-12-31 DOI: 10.52733/KCJ21n4-commentary

Nirmish Singla

引用次数: 0

KCJ Medical Intelligence KCJ医疗情报

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2023-10-06 DOI: 10.52733/kcj21n3-mi

The latest research and breakthrough news emerged in the kidney cancer research specialty.

最新的研究和突破性的消息出现在肾癌研究专业。

引用次数: 0

Current perspective on the impact of endogenous retroviruses in clear cell renal cell carcinoma 内源性逆转录病毒对透明细胞肾细胞癌影响的最新研究进展

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2023-10-06 DOI: 10.52733/kcj21n3-r2

Kathryn Gessner, Mi Zhou, Tracy Rose, Matthew Milowsky, William Kim, Marc Bjurlin

Human endogenous retroviruses (hERVs) have emerged as a mechanism for tumor development and progression in clear cell renal cell carcinoma (ccRCC). Increased expression of various hERVs has been reported in ccRCC with associated activation of anti-tumor immune responses. Retrospective analysis of hERV expression in human ccRCC tumor tissue suggests hERV expression may be associated with improved response to immune checkpoint inhibitors. However, the use of expression to predict response is limited by our ability to annotate and detect hERV expression. This review discusses the biology of hERVs, their role in ccRCC, and the possible impact on ccRCC response to immunotherapy.

人内源性逆转录病毒(herv)已成为透明细胞肾细胞癌(ccRCC)肿瘤发生和进展的一种机制。在ccRCC中，各种herv的表达增加，并伴有相关的抗肿瘤免疫反应的激活。对人ccRCC肿瘤组织中hERV表达的回顾性分析表明，hERV表达可能与免疫检查点抑制剂的改善反应有关。然而，使用表达来预测反应受到我们注释和检测hERV表达的能力的限制。本文综述了herv的生物学特性、在ccRCC中的作用以及对ccRCC免疫应答的可能影响。

引用次数: 0

An Opportunity to Study Mechanisms of Palliative Care by Integrating into Management of The Treatment of Renal Cancer Carcinoma 结合肾癌治疗管理研究姑息治疗机制的机会

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2023-10-06 DOI: 10.52733/kcj21n3-r3

Hiren V. Patel, Brandon Wilton, Eric A. Singer, Login George, Biren Saraiya

Achieving patient-centered care requires helping patients understand their illness, eliciting patient values, and developing a collaborative care plan with input from patient and physician. Combining existing models in communication skills and shared decision making provides a road map for accomplishing these tasks in delivering patient-centered care. In this article, we highlight the importance of patient understanding of their prognosis as a key step in delivering patient-centered care. We then review literature suggesting that both patient and patient’s physicians’ emotions play an inhibitory role in accurate formulation and communication of prognosis by physicians and accurate incorporation of this information by patients. We postulate that the finding of benefit of early integration of palliative care (PC) in improving patient-centered outcomes may be addressing these inhibitory factors. Key skills of empathic communication by a PC team that is focused on addressing patient emotions may facilitate better understanding of prognosis and thus improved patient-centered decision leading to improved patient centered outcomes. Finally, we propose advances treatment of renal cell carcinoma makes it an ideal disease that can inform this hypothesis of how integration of PC works. Specifically, we propose that the curability potential in metastatic RCC, amplifies challenges associated with patient prognostic understanding and decision making. Studying which discipline – primary oncology team or palliative care team – can help patients achieve more accurate prognostic understanding leading to more patient centered choices and improved patient-centered care.

实现以患者为中心的护理需要帮助患者了解他们的疾病，激发患者的价值观，并根据患者和医生的意见制定协作护理计划。结合沟通技巧和共享决策的现有模式，为完成以患者为中心的护理任务提供了路线图。在这篇文章中，我们强调了患者了解其预后的重要性，这是提供以患者为中心的护理的关键步骤。然后，我们回顾文献表明，患者和患者医生的情绪都在医生准确制定和沟通预后以及患者准确纳入该信息方面发挥抑制作用。我们假设发现早期整合姑息治疗(PC)在改善以患者为中心的结果方面的益处可能是解决这些抑制因素。专注于处理患者情绪的PC团队的移情沟通的关键技能可能有助于更好地了解预后，从而改善以患者为中心的决策，从而改善以患者为中心的结果。最后，我们提出了肾细胞癌的治疗进展，使其成为一种理想的疾病，可以为PC整合如何工作的假设提供信息。具体来说，我们提出转移性肾细胞癌的治愈潜力，放大了与患者预后理解和决策相关的挑战。研究哪个学科——原发性肿瘤团队还是姑息治疗团队——可以帮助患者获得更准确的预后理解，从而做出更多以患者为中心的选择，并改善以患者为中心的护理。

{"title":"An Opportunity to Study Mechanisms of Palliative Care by Integrating into Management of The Treatment of Renal Cancer Carcinoma","authors":"Hiren V. Patel, Brandon Wilton, Eric A. Singer, Login George, Biren Saraiya","doi":"10.52733/kcj21n3-r3","DOIUrl":"https://doi.org/10.52733/kcj21n3-r3","url":null,"abstract":"Achieving patient-centered care requires helping patients understand their illness, eliciting patient values, and developing a collaborative care plan with input from patient and physician. Combining existing models in communication skills and shared decision making provides a road map for accomplishing these tasks in delivering patient-centered care. In this article, we highlight the importance of patient understanding of their prognosis as a key step in delivering patient-centered care. We then review literature suggesting that both patient and patient’s physicians’ emotions play an inhibitory role in accurate formulation and communication of prognosis by physicians and accurate incorporation of this information by patients. We postulate that the finding of benefit of early integration of palliative care (PC) in improving patient-centered outcomes may be addressing these inhibitory factors. Key skills of empathic communication by a PC team that is focused on addressing patient emotions may facilitate better understanding of prognosis and thus improved patient-centered decision leading to improved patient centered outcomes. Finally, we propose advances treatment of renal cell carcinoma makes it an ideal disease that can inform this hypothesis of how integration of PC works. Specifically, we propose that the curability potential in metastatic RCC, amplifies challenges associated with patient prognostic understanding and decision making. Studying which discipline – primary oncology team or palliative care team – can help patients achieve more accurate prognostic understanding leading to more patient centered choices and improved patient-centered care.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134945686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma – Current Concepts and Contentions in the Era of Immune Checkpoint Inhibitors 转移性肾细胞癌的细胞减少性肾切除术-免疫检查点抑制剂时代的当前概念和争论

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2023-10-06 DOI: 10.52733/kcj21n3-r1

Daniel Shapiro, Jason Abel, Viraj Master, Brandon Manley, Jad Chahoud, Surena Matin, Jose Karam, Philippe Spiess

Cytoreductive nephrectomy (CN), or the removal of the primary kidney tumor in the setting of metastatic disease, plays a critical role in the treatment of metastatic renal cell carcinoma (mRCC). The benefits of CN, are multifactorial including alleviating symptoms but also eliminating cells potentially prone to future metastasis, and potentially extending a patient's survival. As innovations in mRCC treatment continue to emerge, the importance and timing of CN in patient care remains the subject of ongoing debate in the scientific community. With advancements in modern therapies and the introduction of immune checkpoint inhibitors (ICI), the optimal integration of CN in mRCC management becomes even more important to investigate. This manuscript reviews the key literature related to CN and critically evaluates data that investigated CN efficacy. Furthermore, this article summarizes data to help identify ideal candidates for CN, and explores options for integrating CN within the contemporary systemic therapy landscape.

细胞减减性肾切除术(CN)，或在转移性疾病的情况下切除原发肾肿瘤，在转移性肾细胞癌(mRCC)的治疗中起着关键作用。CN的益处是多因素的，包括缓解症状，但也消除了可能倾向于未来转移的细胞，并可能延长患者的生存期。随着mRCC治疗的创新不断涌现，CN在患者护理中的重要性和时机仍然是科学界持续争论的主题。随着现代治疗的进步和免疫检查点抑制剂(ICI)的引入，CN在mRCC管理中的最佳整合变得更加重要。本文回顾了与CN相关的主要文献，并批判性地评估了研究CN疗效的数据。此外，本文总结了数据，以帮助确定CN的理想候选人，并探讨了将CN纳入当代全身治疗领域的选择。

{"title":"Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma – Current Concepts and Contentions in the Era of Immune Checkpoint Inhibitors","authors":"Daniel Shapiro, Jason Abel, Viraj Master, Brandon Manley, Jad Chahoud, Surena Matin, Jose Karam, Philippe Spiess","doi":"10.52733/kcj21n3-r1","DOIUrl":"https://doi.org/10.52733/kcj21n3-r1","url":null,"abstract":"Cytoreductive nephrectomy (CN), or the removal of the primary kidney tumor in the setting of metastatic disease, plays a critical role in the treatment of metastatic renal cell carcinoma (mRCC). The benefits of CN, are multifactorial including alleviating symptoms but also eliminating cells potentially prone to future metastasis, and potentially extending a patient's survival. As innovations in mRCC treatment continue to emerge, the importance and timing of CN in patient care remains the subject of ongoing debate in the scientific community. With advancements in modern therapies and the introduction of immune checkpoint inhibitors (ICI), the optimal integration of CN in mRCC management becomes even more important to investigate. This manuscript reviews the key literature related to CN and critically evaluates data that investigated CN efficacy. Furthermore, this article summarizes data to help identify ideal candidates for CN, and explores options for integrating CN within the contemporary systemic therapy landscape.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134945680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

KCJ Journal Club KCJ杂志俱乐部

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2023-10-06 DOI: 10.52733/kcj21n3-jc

Robert Figlin

The latest research articles in the renal cancer space

肾癌领域的最新研究文章

引用次数: 0

HIF Pathway Inhibition hold much promise and Point Toward an expanding RCC Armamentarium HIF通路抑制具有很大的前景，并指向扩大RCC的武器

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2023-10-06 DOI: 10.52733/kcj21n3-e

Senthil Pazhanisamy

The journey of Belzutifan towards the goal of getting its FDA approval for patients with refractory renal cell carcinoma has reached another milestone. The FDA has granted priority review to the supplemental new drug application (sNDA) for belzutifan. The sNDA seeks approval for the indication of patients with previously treated advanced renal cell carcinoma following immune checkpoint and anti-angiogenic therapies. The interim findings from LITESPARK-005(NCT04195750) demonstrates that the treatment with belzutifan led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with everolimus in adult patients with advanced renal cell carcinoma whose disease progressed following PD-1/PD-L1 and VEGF tyrosine kinase inhibitor (TKI) treatments.

对于难治性肾细胞癌患者，Belzutifan获得FDA批准的目标之旅已经达到了另一个里程碑。FDA已对belzutifan的补充新药申请(sNDA)给予优先审查。sNDA寻求批准在免疫检查点和抗血管生成治疗后既往治疗过的晚期肾细胞癌患者的适应症。LITESPARK-005(NCT04195750)的中期研究结果表明，在PD-1/PD-L1和VEGF酪氨酸激酶抑制剂(TKI)治疗后病情进展的成年晚期肾癌患者中，与依维莫司相比，贝祖替芬治疗导致无进展生存期(PFS)有统计学意义和临床意义的改善。

引用次数: 0

Kidney Cancer Updates from the 2023 American Society of Clinical Oncology Annual Meeting in Chicago. 来自芝加哥 2023 年美国临床肿瘤学会年会的肾癌最新信息。

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2023-06-01

Roy Elias, Yasser Ged, Nirmish Singla

This report highlights key research from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, with a focus on clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) across clinical trials and translational studies. Essential updates in the metastatic ccRCC clinical space encompass results from the CONTACT-03 study, which evaluated an immunotherapy containing regimen for patients who progressed on an initial immunotherapy containing regimen, alongside updated results from the KEYNOTE-426 and CLEAR trials. In the metastatic nccRCC domain, we review clinical trials of combination immunotherapies and tyrosine kinase inhibitors (TKIs). Additionally, we highlight exciting early-phase studies exploring novel targets in RCC and engineered T-cell methodologies. Finally, we summarize notable efforts in translational research, emphasizing biomarker investigations to determine predictors of immunotherapy response, the application of molecular classifiers in RCC, and the relationship between the microbiome and RCC. There were many important RCC related abstracts presented at this year's ASCO conference, attesting to the continued momentum of research in the field. All conference materials, including abstracts and presentations, can be accessed online through the conference website.

本报告重点介绍了2023年美国临床肿瘤学会（ASCO）年会的重要研究成果，重点关注透明细胞肾细胞癌（ccRCC）和非透明细胞肾细胞癌（nccRCC）的临床试验和转化研究。转移性ccRCC临床领域的重要更新包括CONTACT-03研究的结果，该研究评估了一种含有免疫疗法的治疗方案，用于治疗在最初使用含有免疫疗法的治疗方案后病情恶化的患者，此外还有KEYNOTE-426和CLEAR试验的最新结果。在转移性 nccRCC 领域，我们回顾了联合免疫疗法和酪氨酸激酶抑制剂 (TKIs) 的临床试验。此外，我们还重点介绍了探索 RCC 新靶点和工程 T 细胞方法的令人兴奋的早期研究。最后，我们总结了转化研究方面的显著成果，强调了用于确定免疫疗法反应预测因子的生物标记物研究、分子分类器在 RCC 中的应用以及微生物组与 RCC 之间的关系。今年的 ASCO 大会上发表了许多与 RCC 相关的重要摘要，证明了该领域研究的持续发展势头。所有会议资料（包括摘要和演讲）均可通过会议网站在线查阅。

{"title":"Kidney Cancer Updates from the 2023 American Society of Clinical Oncology Annual Meeting in Chicago.","authors":"Roy Elias, Yasser Ged, Nirmish Singla","doi":"","DOIUrl":"","url":null,"abstract":"This report highlights key research from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, with a focus on clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) across clinical trials and translational studies. Essential updates in the metastatic ccRCC clinical space encompass results from the CONTACT-03 study, which evaluated an immunotherapy containing regimen for patients who progressed on an initial immunotherapy containing regimen, alongside updated results from the KEYNOTE-426 and CLEAR trials. In the metastatic nccRCC domain, we review clinical trials of combination immunotherapies and tyrosine kinase inhibitors (TKIs). Additionally, we highlight exciting early-phase studies exploring novel targets in RCC and engineered T-cell methodologies. Finally, we summarize notable efforts in translational research, emphasizing biomarker investigations to determine predictors of immunotherapy response, the application of molecular classifiers in RCC, and the relationship between the microbiome and RCC. There were many important RCC related abstracts presented at this year's ASCO conference, attesting to the continued momentum of research in the field. All conference materials, including abstracts and presentations, can be accessed online through the conference website.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10829942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139652391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Robotic-assisted cytoreductive partial nephrectomy for metastatic sarcomatoid renal cell carcinoma following dramatic response to combination immunotherapy in a young female. 机器人辅助的细胞减少性部分肾切除术治疗转移性肉瘤样肾细胞癌，在联合免疫治疗后显着反应。

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2023-06-01

Yasin Bhanji, Ezra Baraban, Brian Antonucci, Yasser Ged, Nirmish Singla

Novel immune checkpoint inhibitors (ICI) have yielded remarkable response rates in metastatic renal cell carcinoma (RCC), including sarcomatoid RCC (sRCC). Here, we show the feasibility and efficacy of robotic-assisted cytoreductive partial nephrectomy (cPN) following a remarkable response to combination ICI for metastatic sRCC in a young female. A female in her late 40s presented with poor-risk, metastatic sRCC emanating from a 6.5 cm left renal mass including pulmonary involvement, retroperitoneal lymphadenopathy, and a scalp metastasis. She received 4 cycles of combination ipilimumab and nivolumab followed by maintenance nivolumab with a remarkable and durable response. Given the apparent downstaging of her primary tumor, a robotic cPN was pursued for residual ypT1aNoRo sRCC and found to be both feasible and safe with exceptional perioperative outcomes. She has since done well clinically and oncologically. Our unique case of metastatic sRCC in a young female highlights several aspects pertinent to the contemporary management of metastatic RCC including the role for cytoreductive nephrectomy in selected patients, the safety and feasibility of a nephron-sparing and minimally-invasive approach to cytoreduction after downstaging with ICI, and remarkable sensitivity of sRCC-a classically aggressive entity-to ICI.

新型免疫检查点抑制剂(ICI)在转移性肾细胞癌(RCC)，包括肉瘤样RCC (sRCC)中产生了显著的应答率。在这里，我们展示了机器人辅助的细胞减少性部分肾切除术(cPN)的可行性和有效性，在联合ICI治疗转移性sRCC的年轻女性中取得了显著的疗效。女性，40多岁，低风险，转移性sRCC来自6.5厘米的左肾肿块，包括肺部累及，腹膜后淋巴结病和头皮转移。她接受了4个周期的伊匹单抗和纳武单抗联合治疗，随后是维持纳武单抗，疗效显著且持久。鉴于其原发肿瘤的明显分期下降，我们对残留的ypT1aNoRo sRCC进行了机器人cPN治疗，发现该方法既可行又安全，并具有特殊的围手术期预后。从那以后，她的临床和肿瘤治疗都做得很好。我们一名年轻女性转移性肾细胞癌的独特病例突出了当代转移性肾细胞癌治疗的几个方面，包括在选择的患者中进行细胞减少性肾切除术的作用，保留肾细胞和微创方法在ICI降期后减少细胞的安全性和可行性，以及sRCC(典型的侵袭性实体)对ICI的显著敏感性。

{"title":"Robotic-assisted cytoreductive partial nephrectomy for metastatic sarcomatoid renal cell carcinoma following dramatic response to combination immunotherapy in a young female.","authors":"Yasin Bhanji, Ezra Baraban, Brian Antonucci, Yasser Ged, Nirmish Singla","doi":"","DOIUrl":"","url":null,"abstract":"Novel immune checkpoint inhibitors (ICI) have yielded remarkable response rates in metastatic renal cell carcinoma (RCC), including sarcomatoid RCC (sRCC). Here, we show the feasibility and efficacy of robotic-assisted cytoreductive partial nephrectomy (cPN) following a remarkable response to combination ICI for metastatic sRCC in a young female. A female in her late 40s presented with poor-risk, metastatic sRCC emanating from a 6.5 cm left renal mass including pulmonary involvement, retroperitoneal lymphadenopathy, and a scalp metastasis. She received 4 cycles of combination ipilimumab and nivolumab followed by maintenance nivolumab with a remarkable and durable response. Given the apparent downstaging of her primary tumor, a robotic cPN was pursued for residual ypT1aNoRo sRCC and found to be both feasible and safe with exceptional perioperative outcomes. She has since done well clinically and oncologically. Our unique case of metastatic sRCC in a young female highlights several aspects pertinent to the contemporary management of metastatic RCC including the role for cytoreductive nephrectomy in selected patients, the safety and feasibility of a nephron-sparing and minimally-invasive approach to cytoreduction after downstaging with ICI, and remarkable sensitivity of sRCC-a classically aggressive entity-to ICI.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138048966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors 转移性RCC的最佳治疗时间:探索检查点抑制剂的无治疗生存期

Kidney cancer journal : official journal of the Kidney Cancer Association

Pub Date : 2022-09-29 DOI: 10.52733/kcj20n3-a1

Grayce Selig, C. Hoimes, Joe Bible, D. George, M. Harrison

The optimal duration of treatment for patients with metastatic renal cell carcinoma (mRCC) on dual immune checkpoint inhibitor (ICI) therapy remains unknown. However, there is evolving evidence that a portion of patients who achieve a complete or partial response will have a durable response, even after therapy discontinuation, leading to prolonged treatment-free survival (TFS). TFS with dual ICI is a phenomenon not seen with targeted agents and has the potential to improve patient reported outcomes and quality of life, without altering overall survival (OS). Despite this understanding, treatment of mRCC remains lifelong, as there has yet to be a prospective, randomized control trial to evaluate this key question. In this review, we analyze available studies in patients with mRCC on dual ICI therapy and propose considerations for early treatment discontinuation. Additionally, we discuss vital questions and the next steps to help physicians and patients navigate these challenging treatment decisions.

对于转移性肾细胞癌(mRCC)患者，双免疫检查点抑制剂(ICI)治疗的最佳持续时间尚不清楚。然而，越来越多的证据表明，部分达到完全或部分缓解的患者即使在停止治疗后也会有持久的缓解，从而延长无治疗生存期(TFS)。双ICI的TFS是靶向药物中未见的现象，有可能改善患者报告的结果和生活质量，而不会改变总生存期(OS)。尽管有这样的认识，mRCC的治疗仍然是终身的，因为还没有一个前瞻性的随机对照试验来评估这个关键问题。在这篇综述中，我们分析了mRCC患者双重ICI治疗的现有研究，并提出了早期停药的考虑。此外，我们讨论重要的问题和下一步，以帮助医生和患者导航这些具有挑战性的治疗决策。

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Kidney cancer journal : official journal of the Kidney Cancer Association

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀